Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-11-22FDA Approved: OXCARBAZEPINE — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approved the original application for a generic oxcarbazepine product from Ingenus Pharmaceuticals, enabling marketing of the generic an…
-
FDA approval · 2024-11-21FDA Approved: OXCARBAZEPINE — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved a supplemental application for oxcarbazepine filed by Ajanta Pharma USA Inc., approving changes related to the marketed product…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: CBD Cannabis Extract: Pharmacokinetic Studies [EARLY_Phase 1]
This early Phase 1 pharmacokinetic study of CBD cannabis extract in individuals with epilepsy has been completed.
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: Optimal Stimulation Parameters to Disrupt Epileptiform Activity [NA]
A Massachusetts General Hospital-sponsored clinical trial aims to identify optimal stimulation parameters to disrupt epileptiform activity i…
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: Using Micro-filaments to Detect "fast Ripples" and Improve the Identification of the Epileptogenic Zone [NA]
A clinical trial update describing a study that uses micro-filaments to detect fast ripples in order to improve identification of the epilep…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-11-18FDA Approved: LORAZEPAM — Original Application (Fresenius Kabi USA, LLC)
FDA approved the Original Application for lorazepam from Fresenius Kabi USA, LLC, granting a generic version of the drug.
-
FDA approval · 2024-11-15FDA Approved: LACOSAMIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's supplemental application for lacosamide, enabling the generic lacosamide product to enter the U.S. m…
-
FDA approval · 2024-11-15FDA Approved: LACOSAMIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for lacosamide from Aurobindo Pharma Limited, enabling the marketing of a generic lacosamide product…
-
FDA approval · 2024-11-15FDA Approved: LACOSAMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for lacosamide from Sun Pharmaceutical Industries, Inc. to modify the approved generic lacosamid…
-
FDA approval · 2024-11-14FDA Approved: LEVETIRACETAM — Supplemental Application (Hisun Pharmaceuticals USA, Inc.)
FDA granted a supplemental approval for Levetiracetam from Hisun Pharmaceuticals USA, Inc. to bring a generic product to market (ANDA207175)…
-
FDA approval · 2024-11-14FDA Approved: LACOSAMIDE — Original Application (Trigen Laboratories, LLC)
FDA approved Trigen Laboratories, LLC's original application for lacosamide, enabling a generic lacosamide product to enter the market.
-
FDA approval · 2024-11-13FDA Approved: LEVETIRACETAM — Supplemental Application (Major Pharmaceuticals)
The FDA approved a supplemental application for levetiracetam from Major Pharmaceuticals (ANDA201157).
-
FDA approval · 2024-11-13FDA Approved: LEVETIRACETAM — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for LEVETIRACETAM submitted by NorthStar RxLLC.
-
EMA approval · 2024-11-13EMA Authorised: Buccolam (midazolam) — Neuraxpharm Pharmaceuticals S.L.
The EMA authorised Buccolam, a midazolam product, for treatment of epileptic seizures; the marketing authorization holder is Neuraxpharm Pha…
-
CLINICAL_TRIALS research · 2024-11-06Clinical Trial Update: Effects of Exercise on Functional Performance, BDNF, Executive Functions and Sleep Quality in Children with Epilepsy [NA]
Clinical trial evaluating the effects of exercise on functional performance, BDNF levels, executive functions, and sleep quality in children…
-
CLINICAL_TRIALS trial_result · 2024-11-05Clinical Trial Update: SCN2A Polymorphisms Are Associated With Response to Valproic Acid in Paediatric Population(Pakistan)
The study reports an association between SCN2A gene polymorphisms and response to valproic acid in children with epilepsy in Pakistan. These…
-
FDA approval · 2024-11-05FDA Approved: TOPIRAMATE — Original Application (Vitruvias Therapeutics, Inc.)
FDA approves Vitruvias Therapeutics' generic Topiramate through an Original Application (ANDA), expanding access as a generic option for epi…
-
CLINICAL_TRIALS research · 2024-11-05Clinical Trial Update: Memory Retrieval and Encoding Investigated by Neural Stimulation [NA]
Clinical trial update from the University of Pennsylvania describing investigation of memory retrieval and encoding using neural stimulation…
-
CLINICAL_TRIALS research · 2024-11-01Clinical Trial Update: A Retrospective Study to Validate BioEP as an Assessment Aid for Seizure Susceptibility
Neuronostics Ltd is conducting a retrospective study to validate BioEP as an assessment aid for seizure susceptibility in epilepsy. The stud…
-
FDA approval · 2024-10-31FDA Approved: TOPIRAMATE — Original Application (Ascend Laboratories, LLC)
The FDA approved Ascend Laboratories' original ANDA for topiramate, providing a generic version of this anticonvulsant and migraine preventi…
-
CLINICAL_TRIALS research · 2024-10-29Clinical Trial Update: Extreme Capsule Electrical Stimulation for Drug-resistant Focal Epilepsy [NA]
A clinical trial evaluating extreme capsule electrical stimulation for drug-resistant focal epilepsy has not yet started recruiting.
-
FDA approval · 2024-10-23FDA Approved: TOPIRAMATE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Topiramate from Zydus Lifesciences Limited under an ANDA.
-
CLINICAL_TRIALS research · 2024-10-23Clinical Trial Update: Mos-FED (Mosaicism in Focal Epilepsy Cortical Dysplasia Tissue) [NA]
This document notes a clinical trial update for Mos-FED studying mosaicism in focal epilepsy cortical dysplasia tissue. The study is current…
-
CLINICAL_TRIALS research · 2024-10-17Clinical Trial Update: Seizure Recurrence After Unprovoked First Seizure
A recruiting clinical study examining seizure recurrence after an unprovoked first seizure, with epilepsy as a key condition.
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: The Effect of Cognitive Rehabilitation on Epileptic Pateints Under Treatment [NA]
This update reports the completion of a clinical trial evaluating the effect of cognitive rehabilitation on patients with epilepsy who are u…